Literature DB >> 34978010

Mesenchymal stem cell-derived extracellular vesicles prevent glioma by blocking M2 polarization of macrophages through a miR-744-5p/TGFB1-dependent mechanism.

Ling Liu1, Meixiong Cheng1, Tian Zhang1, Yong Chen1, Yaqiu Wu2, Qi Wang3.   

Abstract

AIM: Our current study is conducted with intention to explore the regulatory mechanism of mesenchymal stem cell (MSC)-derived extracellular vesicle (EV)-miR-744-5p in glioma.
METHODS: Expression patterns of TGFB1, TGFBR1, and miR-744-5p were determined. EVs were isolated from human MSCs, which were characterized. Then, macrophages were co-cultured with MSCs with ectopic miR-744-5p expression to explore its role in cell proliferation, invasion, and migration capabilities. A nude mouse model of glioma xenograft was developed to observe the tumorigenesis and metastasis ability of glioma in vivo.
RESULTS: TGFB1 and TGFBR1 were upregulated in glioma. TGFB1 promoted M2 polarization of macrophages through theMAPK signaling, thereby promoting the progression of glioma. MSC-EVs suppressed TGFB1 expression in macrophages and inhibited M2 polarization of macrophages. MSC-EVs-miR-744-5p/TGFB1/MAPK axis inhibited M2 polarization of macrophages and reduced the malignant phenotypes of glioma cells. In vivo experiments verified that MSC-EVs-miR-744-5p inhibited the polarization of macrophage M2 and prevented glioma progression.
CONCLUSION: Taken together, MSC-EVs-miR-744-5p may suppress the MAPK signaling activity by downregulating TGFB1, and then inhibit polarization of macrophages M2, thereby preventing the progression of glioma. Graphical Headlights 1. TGFB1 promotes the M2 polarization of macrophages via the MAPK signaling. 2. miR-744-5p carried by MSC-EVs targets and inhibits TGFB1. 3. MSC-EV-miR-744-5p inhibits M2 polarization of macrophages to prevent glioma progression. 4. miR-744-5p loaded by MSC-EVs may be a preventive strategy against glioma.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Glioma; Extracellular vesicles; microRNA-744-5p; TGFB1; TGFBR1; Mitogen-activated protein kinases; Macrophages; M2 polarization

Mesh:

Substances:

Year:  2022        PMID: 34978010     DOI: 10.1007/s10565-021-09652-7

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.819


  32 in total

1.  Extracellular vesicles from mesenchymal stem cells reduce microglial-mediated neuroinflammation after cortical injury in aged Rhesus monkeys.

Authors:  Veronica Go; Bethany G E Bowley; Monica A Pessina; Zheng Gang Zhang; Michael Chopp; Seth P Finklestein; Douglas L Rosene; Maria Medalla; Benjamin Buller; Tara L Moore
Journal:  Geroscience       Date:  2019-11-06       Impact factor: 7.713

2.  Glioma cells promote angiogenesis through the release of exosomes containing long non-coding RNA POU3F3.

Authors:  H-L Lang; G-W Hu; Y Chen; Y Liu; W Tu; Y-M Lu; L Wu; G-H Xu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2017-03       Impact factor: 3.507

Review 3.  Prospect of natural products in glioma: A novel avenue in glioma management.

Authors:  Moumita Kundu; Subhayan Das; Dibakar Dhara; Mahitosh Mandal
Journal:  Phytother Res       Date:  2019-07-29       Impact factor: 5.878

4.  Thermoresponsive nanocomposite gel for local drug delivery to suppress the growth of glioma by inducing autophagy.

Authors:  Li Ding; Qi Wang; Ming Shen; Ying Sun; Xiangyu Zhang; Can Huang; Jianhua Chen; Rongxin Li; Yourong Duan
Journal:  Autophagy       Date:  2017-06-08       Impact factor: 16.016

5.  Docosahexaenoic acid enhances M2 macrophage polarization via the p38 signaling pathway and autophagy.

Authors:  Aki Kawano; Wataru Ariyoshi; Yoshie Yoshioka; Hisako Hikiji; Tatsuji Nishihara; Toshinori Okinaga
Journal:  J Cell Biochem       Date:  2019-03-01       Impact factor: 4.429

6.  TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis.

Authors:  Adela Castillejo; Nathaniel Rothman; Cristiane Murta-Nascimento; Núria Malats; Montserrat García-Closas; Angeles Gómez-Martínez; Josep Lloreta; Adonina Tardón; Consol Serra; Reina García-Closas; Stephen Chanock; Debra T Silverman; Mustafa Dosemeci; Manolis Kogevinas; Alfredo Carrato; José Luis Soto; Francisco X Real
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

7.  Oleanolic acid suppresses migration and invasion of malignant glioma cells by inactivating MAPK/ERK signaling pathway.

Authors:  Guocai Guo; Weicheng Yao; Quanqin Zhang; Yongli Bo
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

8.  Reduction of miR-744 delivered by NSCLC cell-derived extracellular vesicles upregulates SUV39H1 to promote NSCLC progression via activation of the Smad9/BMP9 axis.

Authors:  Liming Gao; Qi Tian; Tong Wu; Shanshan Shi; Xiaobo Yin; Lijie Liu; Lei Zheng; Ping Wang; Yaling Tian; Shufeng Xu
Journal:  J Transl Med       Date:  2021-01-20       Impact factor: 5.531

9.  miR-504 modulates the stemness and mesenchymal transition of glioma stem cells and their interaction with microglia via delivery by extracellular vesicles.

Authors:  Ariel Bier; Xin Hong; Simona Cazacu; Hodaya Goldstein; Daniel Rand; Cunli Xiang; Wei Jiang; Hiba Waldman Ben-Asher; Moshe Attia; Aharon Brodie; Ruicong She; Laila M Poisson; Chaya Brodie
Journal:  Cell Death Dis       Date:  2020-10-22       Impact factor: 8.469

10.  Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Authors:  Brigitta G Baumert; Monika E Hegi; Martin J van den Bent; Andreas von Deimling; Thierry Gorlia; Khê Hoang-Xuan; Alba A Brandes; Guy Kantor; Martin J B Taphoorn; Mohamed Ben Hassel; Christian Hartmann; Gail Ryan; David Capper; Johan M Kros; Sebastian Kurscheid; Wolfgang Wick; Roelien Enting; Michele Reni; Brian Thiessen; Frederic Dhermain; Jacoline E Bromberg; Loic Feuvret; Jaap C Reijneveld; Olivier Chinot; Johanna M M Gijtenbeek; John P Rossiter; Nicolas Dif; Carmen Balana; Jose Bravo-Marques; Paul M Clement; Christine Marosi; Tzahala Tzuk-Shina; Robert A Nordal; Jeremy Rees; Denis Lacombe; Warren P Mason; Roger Stupp
Journal:  Lancet Oncol       Date:  2016-09-27       Impact factor: 54.433

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.